Suraksha Diagnostic Ltd

Suraksha Diagnostic Ltd has announced its 21st Annual General Meeting (AGM) scheduled for Tuesday, September 22, 2026, at 11:30 AM IST, to be conducted via Video Conference (VC)/Other Audio Visual Means (OAVM). In compliance with SEBI Listing Regulations, the Annual Report for the Financial Year 2025-26, along with the AGM notice, is accessible via a weblink (https://www.surakshanet.com/annual-report.php) and on the company's website. The report is also available on the websites of BSE, NSE, NSDL, and KFin Technologies Limited. Key dates for dividend and e-voting have been set, with the record date for dividend and cut-off for e-voting on September 15, 2026, and remote e-voting from September 18 to September 21, 2026. Shareholders are advised to update their KYC details with their Depository Participants if not already registered.

Suraksha Diagnostic Ltd. has filed its Annual Report for the financial year 2025-26, along with the notice for its 21st Annual General Meeting (AGM) scheduled for September 22, 2026. The AGM will be conducted through electronic mode. The report highlights the company's focus on precision, trust, and innovation in diagnostics, emphasizing advancements in genomics, digital pathology, and AI-enabled reporting. The company also details its strategic expansion and capability-led acquisitions aimed at strengthening its integrated diagnostics ecosystem. The Annual Report is accessible via the company's website (www.surakshanet.com) and will be sent electronically to registered members.

Suraksha Diagnostic Ltd has announced its 21st Annual General Meeting (AGM) will be held on September 22, 2026. The company has also enclosed its Annual Report for the financial year 2025-26, which includes the notice for the AGM. The report details the company's focus on precision, trust, and innovation in diagnostics, highlighting advancements in genomics, digital pathology, AI-enabled reporting, and strategic expansion. The Annual Report and AGM notice are being sent electronically to registered members and are also available on the company's website.

Suraksha Diagnostic Limited reported strong unaudited financial results for Q1 FY27, with Profit After Tax (PAT) growing 40% year-on-year to ₹128 million. Total income increased by 21% to ₹887 million, and EBITDA grew by 28% to ₹315 million, with an improved EBITDA margin of 36.0%. The company saw healthy growth in patient and test volumes, alongside increased realization per test and patient. Expansion efforts included commissioning one hub and three spoke centers. Suraksha Genomics also demonstrated significant growth, with revenue up 136% YoY.

Suraksha Diagnostic Ltd announced the appointment of Mr. Dinesh Gupta as the Chief Financial Officer (CFO) and Group Chief Financial Officer, effective August 24, 2026. This decision was approved by the Board of Directors during their meeting held on August 12, 2026. The company also approved unaudited financial results for the quarter ended June 30, 2026, and a revised notice for the 21st Annual General Meeting scheduled for September 22, 2026. A record date of September 15, 2026, was fixed for dividend entitlement for the financial year ended March 31, 2026.

Suraksha Diagnostic Ltd announced that its Board of Directors has fixed September 15, 2026, as the record date for determining shareholder entitlement to dividends for the financial year ended March 31, 2026. The dividend, if approved at the 21st Annual General Meeting (AGM) scheduled for September 22, 2026, will be paid within the statutory period. The board also approved unaudited financial results for the quarter ended June 30, 2026, and appointed Dinesh Gupta as the Chief Financial Officer effective August 24, 2026.

Suraksha Diagnostic Ltd announced the approval of its unaudited financial results for the quarter ended June 30, 2026, on a standalone and consolidated basis. The Board of Directors also approved the revised notice for the 21st Annual General Meeting, scheduled for September 22, 2026. Additionally, September 15, 2026, was fixed as the record date for determining shareholder entitlement to dividends for the financial year ended March 31, 2026. The company also announced the appointment of Mr. Dinesh Gupta as the Chief Financial Officer, effective August 24, 2026.

Suraksha Diagnostic Ltd announced the outcome of its Board meeting held on August 12, 2026. The Board approved the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026. Additionally, Mr. Dinesh Gupta was appointed as the Chief Financial Officer, effective August 24, 2026. The company also approved a revised notice for its 21st Annual General Meeting, scheduled for September 22, 2026, and fixed September 15, 2026, as the record date for determining dividend entitlement.

Suraksha Diagnostic Ltd has announced the postponement of its 21st Annual General Meeting (AGM), originally scheduled for September 2, 2026. The company cited unavoidable circumstances as the reason for the delay. A new date, time, and venue for the AGM will be communicated in due course, in compliance with the Companies Act, 2013 and SEBI regulations. The company has expressed regret for any inconvenience caused to its shareholders.

Suraksha Diagnostic Ltd has announced that its Board of Directors will convene on August 12, 2026. The primary agenda item is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also confirmed that the trading window, which was closed from July 1, 2026, for directors, KMPs, designated persons, and connected individuals, will reopen 48 hours after the financial results are declared. This information is also available on the company's website.